This study examined how the revised 2018 ASCO/CAP HER2 scoring criteria update impacted rates of HER2 equivocal and positive breast cancer diagnoses in a single institution.
American Journal of Clinical Pathology
Original Article: Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update